Johann Hari. Truths 2/29/2016. From the street to the NICU. Treatment works

Similar documents
MAT IN PREGNANCY KAYLA LIFE STAGE 1: ADOLESCENCE LIFE STAGE 2: EARLY ADULTHOOD. family History of addiction. addiction to oral opioids

THE OPIOID CRISIS 9/19/2018 DEFINING THE CRISIS DEFINING THE CRISIS NUMBER OF OPIOID-RELATED OVERDOSE DEATHS IN ALABAMA

Medication for the Treatment of Addiction (MAT)

9/19/13. Postpartum Counseling for Women in MAT. Katie Clark MSPH, CSAC. A little about Katie. Definitions. MAT: Medication-Assisted Treatment

Medication-Assisted Treatment & Pregnancy. Dave Kneessy, MS, MAC, CAP, LMHC Regional Director Central Florida Treatment Centers

Methadone and Pregnancy

Maternal-fetal Opiate Medical Home (MOMH) Jocelyn Davis DNP,CNM, RN, CEFMM Karen Frantz BSN, RNC

Lori A. Shook, MD Division of Neonatology Kentucky Children s Hospital University of Kentucky Medical Center

Anesthetics, Local a / or Anesthesia, Epidural a / or Anesthesia, Obstetrical a / or Pain, Postoperative a / or Postpartum Period a

Advancing the Care of Pregnant and Parenting Women with Opioid Use Disorder and their Infants: A Foundation for Clinical Guidance

The Opioid-Exposed Woman

Brief History of Methadone Maintenance Treatment

KRISANNA DEPPEN, MD FAMILY MEDICINE, ADDICTION MEDICINE GRANT MEDICAL CENTER-OHIOHEALTH COLUMBUS, OH

Opioid Treatment in North Carolina SEPTEMBER 13, 2016

Disclosures. Topics of today s training 4/24/2017. Evolving Treads in Medication Assisted Treatment. Christopher J Davis D.O.

An Adaptive Reinforcement-Based Treatment (RBT) Intervention for Pregnant Substance Dependent Women

Disclosures. Objectives 2/5/2018. Women and opioid use disorder: Optimizing care during pregnancy and beyond

Non-Pharmacologic Treatment for Infants with Neonatal Abstinence Syndrome (NAS)

Opioid Use Disorder in Pregnancy. Neonatal Abstinence Syndrome

NOWS The Time Caring for the Infant with Neonatal Opiate Withdrawal Syndrome

Medication Assisted Treatment. MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment

Effects of Prenatal Illicit Drug. Use on Infant and Child

201 KAR 9:270. Professional standards for prescribing or dispensing Buprenorphine-Mono-Product or Buprenorphine-Combined-with-Naloxone.

Opioid Use Disorder- Pregnancy Principles and Myths. Brian Iriye MD and Farzad Kamyar MD High Risk Pregnancy Center

Objectives. Care of the Neonate with Prenatal Opioid Exposure. What is Neonatal Abstinence Syndrome (NAS)? Increasing Incidence of NAS 8/27/2016

Continuing Education Webinar The Pregnancy Opioid Epidemic: An Outpatient Medical Home Approach to Treatment

Opioid Use in Pregnant Women and Prenatal Care. Murray F Dweck MD, FACOG Medical Director/OBGYN Florida Department of Health -Brevard

2/28/2017. Substance Use Disorders + Pregnancy. Substance Use Disorders + Pregnancy. + Prevalence of the Problem

ADDICTION IN PREGNANCY

Talking with your doctor

Child Welfare and MOMS: Building Partnerships to Improve Care

MAT in the Corrections Setting

Maternal Substance Abuse: Challenges & Opportunities for Perinatal Nurses Catherine H. Ivory, PhD, RNC-OB October, 2015

The available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines

What Is Heroin? Examples of Opioids. What Science Says about Opioid Use Disorder and Its Treatment 6/27/2016

Opioid use in pregnancy and Neonatal Abstinence Syndrome

Texas Strategies to Address the Opioid Crisis and Neonatal Abstinence Syndrome

Neonatal Abstinence Syndrome Questions & Answers Webinar #1 (February 9, 2012) Webinar #2 (March 30, 3012)

GOALS AND OBJECTIVES

Vivitrol/Suboxone. Comparison Study Summary

Neonatal Abstinence Syndrome (NAS)

Addiction and Pregnancy. Jim Walsh, MD Medical Director Addiction Recovery Service Swedish Medical Center WSADCP October 2018

Buprenorphine: An Introduction. Sharon Stancliff, MD Harm Reduction Coalition September 2008

Why NAS? Proposed Program

INTRODUCTION. Baltimore, Maryland 6 School of Medicine West Virginia University, Morgantown, West Virginia

Opioid Agonists. Natural derivatives of opium poppy - Opium - Morphine - Codeine

Medication Assisted Treatment. Nicole Gastala, MD

Buprenorphine in Pregnancy: The Basics

Vivitrol Vs. Suboxone

Medication Assisted Treatment:

Beyond Birth: A Comprehensive Recovery Center serving parenting women

Opiate Use in Reproductive Age Females

Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center

HOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain

Buprenorphine addiction

Central Appalachia: A Regional Response to an Opioid Epidemic in Pregnancy

THE OPIOID DEPENDENT MOTHER AND NEWBORN - AN UPDATE

1/23/2017. Medication Assisted Treatment (MAT) If Addiction is a Disease, Why am I not at the Doctor?! INTRODUCTION

(Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines)

SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets. Risk Evaluation and Mitigation Strategy (REMS) Program

Treating Opioid Use Disorders: An Update for Counselors and Other Providers

Medication Assisted Treatment of Substance Use Disorders

Funding for TIPS provided by: The State of Tennessee Portions of this presentation 2002 The American College of Obstetricians and Gynecologists

Managing drug misuse in pregnancy and beyond

THA Medication Safety Summit. Wesley Geminn, PharmD, BCPP

Medication-Assisted Treatment. What Is It and Why Do We Use It?

Pharmacotherapy for opioid addiction. Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco

Methadone Maintenance 101

Outcomes of Infants with Neonatal Abstinence Syndrome

Learning Objectives. Serving Pregnant Women Affected by Substance Use Disorders in Healing to Wellness Court: Sharing Lessons

Medications for Opioid Use Disorder. Charles Brackett, MD, MPH General Internal Medicine, DHMC

4/19/2018. Opioid Use Disorder in Pregnancy OBJECTIVES ANTENATAL TESTING

The Substance Exposed Newborn Alphabet Soup

REDUCING THE STIGMA OF OPIOID ADDICTION AMONG PERINATAL WOMEN. Lyn Raible, M.D., Ph.D. CMO, Aegis

Addiction to Opioids. Marvin D. Seppala, MD Chief Medical Officer

Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates

Arwen Podesta, MD. ABIHM, ABAM, Forensic Psychiatry

Substance-Exposed Newborn

SUBOXONE (buprenorphine and naloxone) sublingual film (CIII) IMPORTANT SAFETY INFORMATION

Opioid Use Disorders and Pregnancy. Marcela Smid, MD Maternal-Fetal Medicine

2/19/18. Today s talk. Today s talk. The Role of Behavioral Interventions in Buprenorphine Treatment of Opioid Use Disorders

The Social Worker s Role in Medication Assisted Treatment

OPIOID MICRO TRAINING MODULE 4: UNDERSTANDING OPIOID USE, PREGNANCY, AND NEONATAL ABSTINENCE SYNDROME (NAS)

MOMS Project Panel Overview

Discover the Hope: Opiate Treatment and Recovery

Prenatal Substance Abuse: Improving Outcomes

EI Leadership April 24, 2018

Neonatal Abstinence Syndrome

Bench Guide for Opioid-Involved Dependency Cases *

What If This Was The Message?

2/24/2017. Pregnant Women Who Use Drugs: Stigma, Science and Society

Neonatal Abstinence: The epidemic Its Impact on All of Us

Management Options for Opioid Dependence:

Opioid Addiction and Dependence in Pregnancy

OPIOID SUBSTITUTION THERAPY RISKS & BENEFITS

Substance Abuse In Pregnancy. N.L. Meyer, MD University of Tennessee Health Science Center November 18, 2016

FY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine

Vermont Guidelines for Obstetric Providers

HELPING OUR MOST VULNERABLE POPULATIONS IMPACTED BY THE OPIOID CRISIS: PREGNANT WOMEN, THEIR INFANTS, AND THOSE RECEIVING CHILD WELFARE SERVICES

Medication Assisted Treatment

Transcription:

From the street to the NICU Richard Christensen, PA, CAS Johann Hari Treatment works Truths Disconnect with pregnant women seeking treatment Disconnect between community and science Medication is not a stand alone treatment Substance use disorders as a group of brain disorders Science Vs. Philosophy The science and evidence is not for MAT in general, but methadone specifically All programs are not created equal No outcome studies for Vivitrol or buprenorphine 1

Comprehensive treatment is just that, regardless of what medication is used Two critical points Regularity of prenatal care Absence of drugs and alcohol, including tobacco Strategies to Accomplish this: Coordination with OB Ensure Pt is receiving adequate dose Focus on FAS to reduce the likelihood of NAS No study on FAS since 1975 2

This is not about high vs. low dose, this is about ADEQUATE dose a dose of addiction medication where the patient is well for at least 24 hours, has little or no cravings, feels neither high nor sedated, and does not feel the effects of opiates if they should use. Pharmacology of methadone Where people land on their dose of methadone is genetic. Methadone is metabolized by 2 proteins, cytochrome 3a4,2d6 in the liver and is highly protein bound. Dr. Mary Jeanne Kreek, Rockefeller University: Identified the opiate gene and found 2 variants. In one variant they needed higher doses of methadone and in one gene variant they required lower methadone doses. Has nothing to do with Height, weight, or opiate habit. How methadone is metabolized has to do with these proteins and genetics. You do not need to genetic testing. The patient will tell you when they are stable. CSAT Guidelines Ceiling methadone doses inconsistent with current science and medicine Breastfeeding needs to be encouraged 3

ACOG Recommendations on Tx of pregnant patients dependent on opiates The standard for care for the opiate addict is methadone maintenance Based on new information, buprenorphine should be considered for those who might be appropriate Detoxing pregnant opiate addicts should never be considered due to high rate of relapse and uncontrollable FAS during the withdrawal period Methadone and breastfeeding are compatible MOTHER Study 50% of neonates in both groups did not require medication For those that did, buprenorphine neonates were in the NICU for a shorter period and required less medication What s missing in this study No description of care and tx during the pregnancy Methadone doses were in the 70 mg range and not split Description of neonatal environment post delivery in my experience, 50% of neonates born on medication do not require tx. 25% can be managed in a calm environment, soft lights, frequent feeding, swaddling likely won t require NICU 25% will land in NICU Complicated by all of the above 4

Center for Hope SAMHSA Study The majority of birth outcomes fell within the target range even for births where women received medically managed methadone for opiate withdrawal. 88% had no pregnancy complications 89% reached the target gestational age 100% had Apgar scores within the target range 80% were in the target range for birth weight, 68% for length, 76% for head circumference 98% had negative toxicology screens 95% of newborns had no health issues at birth John McCarthy, MD Retrospective Higher doses of methadone during pregnancy and maternal and fetal outcomes. Retrospective view of clinical data for 81 mothers who received methadone, and their offspring. Cohort divided into high dose (>100mg) and low dose (<100mg) Results There were no differences in the rate of medication treatment for neonatal abstinence symptoms or days of infant hospitalization between the highdose (mean, 132 mg) and low dose (mean, 62 mg) groups. Despite longer histories of opiate abuse, the high dose group had less illicit drug use at delivery. The whole cohort, which received an average of 101 mg/d, had an 81 % rate of negative toxicology screens at delivery. 5

Conclusion High doses of methadone were not associated with increased risks of neonatal abstinence symptoms but had a positive effect on maternal drug abuse. Arbitrarily limiting methadone dose as a way of minimizing the risks of neonatal abstinence symptoms may be unwarranted. Recommendations Bi Valley Medical Clinic, Sacramento, CA On going study generates these recommendations: 1. Treat the maternal addiction and stop the fetal exposure to drugs and alcohol 2. Stabilize the disordered maternal and fetal brain chemistry through adequate dosing 3. Avoid NICU, encourage rooming in, skin to skin contact beginning at birth, breastfeeding Average dose in on going study was 140 mg/day, always split 2 4 times a day. With this approach, only 28% have required tx for NAS Profile of Patient appropriate for Subutex Already taking Suboxone or Subutex when they become pregnant (switch to Subutex) After informed consent with all options for MAT, patient chooses Subutex Pt. responsibly taking pain meds who becomes pregnant should convert to Subutex unless pain is intractable, in which case they should switch to methadone Pt. being admitted to drug tx facility and chooses Subutex Low dose street oxycodone or hydrocodone, or small amounts of heroin for short period, and chooses Subutex Pt. is allergic to methadone or it s components Subutex should only be offered as a adjunct to comprehensive drug treatment in the form of counseling, pregnancy groups, outside support, resource development to provide food, clothing, shelter and transportation. 6

Profile of Patient appropriate for methadone A person currently on methadone and gets pregnant After informed consent, anyone who chooses it Heroin or opiate dependent people with large habits and long hx of addiction IV drug users Those with co morbid psychiatric Dx Those with complicated social issues Jail and prison patients Mother/Infant Rooming In Reduces Need for NAS Treatment Seiko in England reports a rate of treatment of 11%: the lowest rate of treatment ever reported. Abrahams in Vancouver reports a treatment rate of 30% Do neonates go into withdrawal from the mother? (Maternal Absence Syndrome) Do NICU environments exacerbate NAS? How necessary are NICUs for NAS management? Can NAS scoring be done with the mother present? Recommendation for hospitals and community Coordinated system of care rather than island approach Focused NAS community group to help facilitate this Hospital OBs and MATs need to require ROI Recognize that care starts at first point of contact, not in the NICU Focused education at the treatment centers to ensure science based tx Educate hospitals and OB so we re all on the same page 7